Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Tailoring cells for clinical needs: Meeting report from the Advanced Therapy in Healthcare symposium (October 28-29 2017, Doha, Qatar).

Deola S, Guerrouahen BS, Sidahmed H, Al-Mohannadi A, Elnaggar M, Elsadig R, Abdelalim EM, Petrovski G, Gadina M, Thrasher A, Wels WS, Hunger SP, Wang E, Marincola FM; ATH Consortium, Maccalli C, Cugno C.

J Transl Med. 2018 Oct 10;16(1):276. doi: 10.1186/s12967-018-1652-y.

2.

In vivo generation of human CD19-CAR T cells results in B-cell depletion and signs of cytokine release syndrome.

Pfeiffer A, Thalheimer FB, Hartmann S, Frank AM, Bender RR, Danisch S, Costa C, Wels WS, Modlich U, Stripecke R, Verhoeyen E, Buchholz CJ.

EMBO Mol Med. 2018 Sep 17. pii: e9158. doi: 10.15252/emmm.201809158. [Epub ahead of print]

3.

Mitophagy in Intestinal Epithelial Cells Triggers Adaptive Immunity during Tumorigenesis.

Ziegler PK, Bollrath J, Pallangyo CK, Matsutani T, Canli Ö, De Oliveira T, Diamanti MA, Müller N, Gamrekelashvili J, Putoczki T, Horst D, Mankan AK, Öner MG, Müller S, Müller-Höcker J, Kirchner T, Slotta-Huspenina J, Taketo MM, Reinheckel T, Dröse S, Larner AC, Wels WS, Ernst M, Greten TF, Arkan MC, Korn T, Wirth D, Greten FR.

Cell. 2018 Jun 28;174(1):88-101.e16. doi: 10.1016/j.cell.2018.05.028. Epub 2018 Jun 14.

PMID:
29909986
4.

Clinical translation and regulatory aspects of CAR/TCR-based adoptive cell therapies-the German Cancer Consortium approach.

Krackhardt AM, Anliker B, Hildebrandt M, Bachmann M, Eichmüller SB, Nettelbeck DM, Renner M, Uharek L, Willimsky G, Schmitt M, Wels WS, Schüssler-Lenz M.

Cancer Immunol Immunother. 2018 Apr;67(4):513-523. doi: 10.1007/s00262-018-2119-y. Epub 2018 Jan 29. Review.

PMID:
29380009
5.

TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer.

Byrd TT, Fousek K, Pignata A, Szot C, Samaha H, Seaman S, Dobrolecki L, Salsman VS, Oo HZ, Bielamowicz K, Landi D, Rainusso N, Hicks J, Powell S, Baker ML, Wels WS, Koch J, Sorensen PH, Deneen B, Ellis MJ, Lewis MT, Hegde M, Fletcher BS, St Croix B, Ahmed N.

Cancer Res. 2018 Jan 15;78(2):489-500. doi: 10.1158/0008-5472.CAN-16-1911. Epub 2017 Nov 28. Erratum in: Cancer Res. 2018 Jun 15;78(12):3403.

PMID:
29183891
6.

Generation and characterization of ErbB2-CAR-engineered cytokine-induced killer cells for the treatment of high-risk soft tissue sarcoma in children.

Merker M, Pfirrmann V, Oelsner S, Fulda S, Klingebiel T, Wels WS, Bader P, Rettinger E.

Oncotarget. 2017 Aug 2;8(39):66137-66153. doi: 10.18632/oncotarget.19821. eCollection 2017 Sep 12.

7.

Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies.

Nowakowska P, Romanski A, Miller N, Odendahl M, Bonig H, Zhang C, Seifried E, Wels WS, Tonn T.

Cancer Immunol Immunother. 2018 Jan;67(1):25-38. doi: 10.1007/s00262-017-2055-2. Epub 2017 Sep 6.

PMID:
28879551
8.

A Two-Phase Expansion Protocol Combining Interleukin (IL)-15 and IL-21 Improves Natural Killer Cell Proliferation and Cytotoxicity against Rhabdomyosarcoma.

Wagner J, Pfannenstiel V, Waldmann A, Bergs JWJ, Brill B, Huenecke S, Klingebiel T, Rödel F, Buchholz CJ, Wels WS, Bader P, Ullrich E.

Front Immunol. 2017 Jun 12;8:676. doi: 10.3389/fimmu.2017.00676. eCollection 2017.

9.

Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity.

Zhang C, Oberoi P, Oelsner S, Waldmann A, Lindner A, Tonn T, Wels WS.

Front Immunol. 2017 May 18;8:533. doi: 10.3389/fimmu.2017.00533. eCollection 2017.

10.

HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial.

Ahmed N, Brawley V, Hegde M, Bielamowicz K, Kalra M, Landi D, Robertson C, Gray TL, Diouf O, Wakefield A, Ghazi A, Gerken C, Yi Z, Ashoori A, Wu MF, Liu H, Rooney C, Dotti G, Gee A, Su J, Kew Y, Baskin D, Zhang YJ, New P, Grilley B, Stojakovic M, Hicks J, Powell SZ, Brenner MK, Heslop HE, Grossman R, Wels WS, Gottschalk S.

JAMA Oncol. 2017 Aug 1;3(8):1094-1101. doi: 10.1001/jamaoncol.2017.0184.

11.

Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.

Oelsner S, Friede ME, Zhang C, Wagner J, Badura S, Bader P, Ullrich E, Ottmann OG, Klingemann H, Tonn T, Wels WS.

Cytotherapy. 2017 Feb;19(2):235-249. doi: 10.1016/j.jcyt.2016.10.009. Epub 2016 Nov 22.

PMID:
27887866
12.

Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape.

Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, Navai SA, Wakefield A, Fousek K, Bielamowicz K, Chow KK, Brawley VS, Byrd TT, Krebs S, Gottschalk S, Wels WS, Baker ML, Dotti G, Mamonkin M, Brenner MK, Orange JS, Ahmed N.

J Clin Invest. 2016 Aug 1;126(8):3036-52. doi: 10.1172/JCI83416. Epub 2016 Jul 18.

13.

Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.

Oelsner S, Wagner J, Friede ME, Pfirrmann V, Genßler S, Rettinger E, Buchholz CJ, Pfeifer H, Schubert R, Ottmann OG, Ullrich E, Bader P, Wels WS.

Int J Cancer. 2016 Oct 15;139(8):1799-809. doi: 10.1002/ijc.30217. Epub 2016 Jun 11.

14.

Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival.

Genßler S, Burger MC, Zhang C, Oelsner S, Mildenberger I, Wagner M, Steinbach JP, Wels WS.

Oncoimmunology. 2015 Dec 21;5(4):e1119354. eCollection 2016 Apr.

15.

CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies.

Romanski A, Uherek C, Bug G, Seifried E, Klingemann H, Wels WS, Ottmann OG, Tonn T.

J Cell Mol Med. 2016 Jul;20(7):1287-94. doi: 10.1111/jcmm.12810. Epub 2016 Mar 23.

16.

Early treatment of HER2-amplified brain tumors with targeted NK-92 cells and focused ultrasound improves survival.

Alkins R, Burgess A, Kerbel R, Wels WS, Hynynen K.

Neuro Oncol. 2016 Jul;18(7):974-81. doi: 10.1093/neuonc/nov318. Epub 2016 Jan 26.

17.

ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma.

Zhang C, Burger MC, Jennewein L, Genßler S, Schönfeld K, Zeiner P, Hattingen E, Harter PN, Mittelbronn M, Tonn T, Steinbach JP, Wels WS.

J Natl Cancer Inst. 2015 Dec 6;108(5). doi: 10.1093/jnci/djv375. Print 2016 May.

PMID:
26640245
18.

NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy.

Suck G, Odendahl M, Nowakowska P, Seidl C, Wels WS, Klingemann HG, Tonn T.

Cancer Immunol Immunother. 2016 Apr;65(4):485-92. doi: 10.1007/s00262-015-1761-x. Epub 2015 Nov 11. Review.

PMID:
26559813
19.

Exclusive Transduction of Human CD4+ T Cells upon Systemic Delivery of CD4-Targeted Lentiviral Vectors.

Zhou Q, Uhlig KM, Muth A, Kimpel J, Lévy C, Münch RC, Seifried J, Pfeiffer A, Trkola A, Coulibaly C, von Laer D, Wels WS, Hartwig UF, Verhoeyen E, Buchholz CJ.

J Immunol. 2015 Sep 1;195(5):2493-501. doi: 10.4049/jimmunol.1500956. Epub 2015 Jul 31.

20.

Cytomegalovirus-specific cytokine-induced killer cells: concurrent targeting of leukemia and cytomegalovirus.

Pfirrmann V, Oelsner S, Rettinger E, Huenecke S, Bonig H, Merker M, Wels WS, Cinatl J, Schubert R, Klingebiel T, Bader P.

Cytotherapy. 2015 Aug;17(8):1139-51. doi: 10.1016/j.jcyt.2015.04.011. Epub 2015 Jun 10.

PMID:
26072027
21.

Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.

Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, Liu E, Dakhova O, Ashoori A, Corder A, Gray T, Wu MF, Liu H, Hicks J, Rainusso N, Dotti G, Mei Z, Grilley B, Gee A, Rooney CM, Brenner MK, Heslop HE, Wels WS, Wang LL, Anderson P, Gottschalk S.

J Clin Oncol. 2015 May 20;33(15):1688-96. doi: 10.1200/JCO.2014.58.0225. Epub 2015 Mar 23.

22.

Advantages and applications of CAR-expressing natural killer cells.

Glienke W, Esser R, Priesner C, Suerth JD, Schambach A, Wels WS, Grez M, Kloess S, Arseniev L, Koehl U.

Front Pharmacol. 2015 Feb 12;6:21. doi: 10.3389/fphar.2015.00021. eCollection 2015. Review.

23.

Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma.

Seidel D, Shibina A, Siebert N, Wels WS, Reynolds CP, Huebener N, Lode HN.

Cancer Immunol Immunother. 2015 May;64(5):621-34. doi: 10.1007/s00262-015-1669-5. Epub 2015 Feb 25.

PMID:
25711293
24.

Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor.

Schönfeld K, Sahm C, Zhang C, Naundorf S, Brendel C, Odendahl M, Nowakowska P, Bönig H, Köhl U, Kloess S, Köhler S, Holtgreve-Grez H, Jauch A, Schmidt M, Schubert R, Kühlcke K, Seifried E, Klingemann HG, Rieger MA, Tonn T, Grez M, Wels WS.

Mol Ther. 2015 Feb;23(2):330-8. doi: 10.1038/mt.2014.219. Epub 2014 Nov 6.

25.

Immunomagnetic selection or irradiation eliminates alloreactive cells but also reduces anti-tumor potential of cytokine-induced killer cells: implications for unmanipulated cytokine-induced killer cell infusion.

Rettinger E, Kreyenberg H, Merker M, Kuçi S, Willasch A, Bug G, Ullrich E, Wels WS, Bonig H, Klingebiel T, Bader P.

Cytotherapy. 2014 Jun;16(6):835-44. doi: 10.1016/j.jcyt.2014.01.003. Epub 2014 Feb 28.

PMID:
24582456
26.

Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity.

Boissel L, Betancur-Boissel M, Lu W, Krause DS, Van Etten RA, Wels WS, Klingemann H.

Oncoimmunology. 2013 Oct 1;2(10):e26527. Epub 2013 Oct 22.

27.

A bispecific transmembrane antibody simultaneously targeting intra- and extracellular epitopes of the epidermal growth factor receptor inhibits receptor activation and tumor cell growth.

Müller N, Hartmann C, Genssler S, Koch J, Kinner A, Grez M, Wels WS.

Int J Cancer. 2014 Jun 1;134(11):2547-59. doi: 10.1002/ijc.28585. Epub 2013 Nov 18.

28.

Arming NK cells with enhanced antitumor activity: CARs and beyond.

Oberoi P, Wels WS.

Oncoimmunology. 2013 Aug 1;2(8):e25220. Epub 2013 Jun 10.

29.

Vaccination directed against the human endogenous retrovirus-K envelope protein inhibits tumor growth in a murine model system.

Kraus B, Fischer K, Büchner SM, Wels WS, Löwer R, Sliva K, Schnierle BS.

PLoS One. 2013 Aug 30;8(8):e72756. doi: 10.1371/journal.pone.0072756. eCollection 2013.

30.

TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy.

Grada Z, Hegde M, Byrd T, Shaffer DR, Ghazi A, Brawley VS, Corder A, Schönfeld K, Koch J, Dotti G, Heslop HE, Gottschalk S, Wels WS, Baker ML, Ahmed N.

Mol Ther Nucleic Acids. 2013 Jul 9;2:e105. doi: 10.1038/mtna.2013.32.

31.

EGFR-targeted granzyme B expressed in NK cells enhances natural cytotoxicity and mediates specific killing of tumor cells.

Oberoi P, Jabulowsky RA, Bähr-Mahmud H, Wels WS.

PLoS One. 2013;8(4):e61267. doi: 10.1371/journal.pone.0061267. Epub 2013 Apr 3.

32.

Focused ultrasound delivers targeted immune cells to metastatic brain tumors.

Alkins R, Burgess A, Ganguly M, Francia G, Kerbel R, Wels WS, Hynynen K.

Cancer Res. 2013 Mar 15;73(6):1892-9. doi: 10.1158/0008-5472.CAN-12-2609. Epub 2013 Jan 9.

33.

T-cell receptor gene transfer exclusively to human CD8(+) cells enhances tumor cell killing.

Zhou Q, Schneider IC, Edes I, Honegger A, Bach P, Schönfeld K, Schambach A, Wels WS, Kneissl S, Uckert W, Buchholz CJ.

Blood. 2012 Nov 22;120(22):4334-42. doi: 10.1182/blood-2012-02-412973. Epub 2012 Aug 16.

34.

Surface charge-modification prevents sequestration and enhances tumor-cell specificity of a recombinant granzyme B-TGFα fusion protein.

Jabulowsky RA, Oberoi P, Bähr-Mahmud H, Dälken B, Wels WS.

Bioconjug Chem. 2012 Aug 15;23(8):1567-76. doi: 10.1021/bc3000657. Epub 2012 Jul 16.

PMID:
22759275
35.

Cytotoxic Capacity of IL-15-Stimulated Cytokine-Induced Killer Cells Against Human Acute Myeloid Leukemia and Rhabdomyosarcoma in Humanized Preclinical Mouse Models.

Rettinger E, Meyer V, Kreyenberg H, Volk A, Kuçi S, Willasch A, Koscielniak E, Fulda S, Wels WS, Boenig H, Klingebiel T, Bader P.

Front Oncol. 2012 Apr 9;2:32. doi: 10.3389/fonc.2012.00032. eCollection 2012.

36.

IL-15 augments antitumoral activity of an ErbB2/HER2 cancer vaccine targeted to professional antigen-presenting cells.

Burkhardt UE, Sloots A, Jakobi V, Wei WZ, Cavallo F, Kloke BP, Wels WS.

Cancer Immunol Immunother. 2012 Sep;61(9):1473-84. doi: 10.1007/s00262-012-1215-7. Epub 2012 Feb 14.

PMID:
22331080
37.

Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor.

Sahm C, Schönfeld K, Wels WS.

Cancer Immunol Immunother. 2012 Sep;61(9):1451-61. doi: 10.1007/s00262-012-1212-x. Epub 2012 Feb 5.

PMID:
22310931
38.

Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens.

Boissel L, Betancur M, Lu W, Wels WS, Marino T, Van Etten RA, Klingemann H.

Leuk Lymphoma. 2012 May;53(5):958-65. doi: 10.3109/10428194.2011.634048. Epub 2011 Dec 6.

39.

NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin.

Esser R, Müller T, Stefes D, Kloess S, Seidel D, Gillies SD, Aperlo-Iffland C, Huston JS, Uherek C, Schönfeld K, Tonn T, Huebener N, Lode HN, Koehl U, Wels WS.

J Cell Mol Med. 2012 Mar;16(3):569-81. doi: 10.1111/j.1582-4934.2011.01343.x.

40.

Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins.

Schneider B, Münkel S, Krippner-Heidenreich A, Grunwald I, Wels WS, Wajant H, Pfizenmaier K, Gerspach J.

Cell Death Dis. 2010 Aug 26;1:e68. doi: 10.1038/cddis.2010.45.

41.

Maltose-binding protein enhances secretion of recombinant human granzyme B accompanied by in vivo processing of a precursor MBP fusion protein.

Dälken B, Jabulowsky RA, Oberoi P, Benhar I, Wels WS.

PLoS One. 2010 Dec 22;5(12):e14404. doi: 10.1371/journal.pone.0014404.

42.

Depicting adoptive immunotherapy for prostate cancer in an animal model with magnetic resonance imaging.

Meier R, Golovko D, Tavri S, Henning TD, Knopp C, Piontek G, Rudelius M, Heinrich P, Wels WS, Daldrup-Link H.

Magn Reson Med. 2011 Mar;65(3):756-63. doi: 10.1002/mrm.22652. Epub 2010 Oct 6.

43.

Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response.

Hartmann C, Müller N, Blaukat A, Koch J, Benhar I, Wels WS.

Oncogene. 2010 Aug 12;29(32):4517-27. doi: 10.1038/onc.2010.195. Epub 2010 May 31.

PMID:
20514015
44.

Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression.

Ahmed N, Salsman VS, Yvon E, Louis CU, Perlaky L, Wels WS, Dishop MK, Kleinerman EE, Pule M, Rooney CM, Heslop HE, Gottschalk S.

Mol Ther. 2009 Oct;17(10):1779-87. doi: 10.1038/mt.2009.133. Epub 2009 Jun 16.

45.

Induction of programmed cell death in ErbB2/HER2-expressing cancer cells by targeted delivery of apoptosis-inducing factor.

Mahmud H, Dälken B, Wels WS.

Mol Cancer Ther. 2009 Jun;8(6):1526-35. doi: 10.1158/1535-7163.MCT-08-1149. Epub 2009 Jun 9.

46.

WT1 peptide-specific T cells generated from peripheral blood of healthy donors: possible implications for adoptive immunotherapy after allogeneic stem cell transplantation.

Weber G, Karbach J, Kuçi S, Kreyenberg H, Willasch A, Koscielniak E, Tonn T, Klingebiel T, Wels WS, Jäger E, Bader P.

Leukemia. 2009 Sep;23(9):1634-42. doi: 10.1038/leu.2009.70. Epub 2009 Apr 9.

PMID:
19357702
47.

Optical imaging of cellular immunotherapy against prostate cancer.

Tavri S, Jha P, Meier R, Henning TD, Müller T, Hostetter D, Knopp C, Johansson M, Reinhart V, Boddington S, Sista A, Wels WS, Daldrup-Link HE.

Mol Imaging. 2009 Jan-Feb;8(1):15-26.

PMID:
19344572
48.

Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells.

Boissel L, Betancur M, Wels WS, Tuncer H, Klingemann H.

Leuk Res. 2009 Sep;33(9):1255-9. doi: 10.1016/j.leukres.2008.11.024. Epub 2009 Jan 14.

49.

DNA vaccines targeting tumor antigens to B7 molecules on antigen-presenting cells induce protective antitumor immunity and delay onset of HER-2/Neu-driven mammary carcinoma.

Sloots A, Mastini C, Rohrbach F, Weth R, Curcio C, Burkhardt U, Jäger E, Forni G, Cavallo F, Wels WS.

Clin Cancer Res. 2008 Nov 1;14(21):6933-43. doi: 10.1158/1078-0432.CCR-08-1257.

50.

Cisplatin-resistant neuroblastoma cells express enhanced levels of epidermal growth factor receptor (EGFR) and are sensitive to treatment with EGFR-specific toxins.

Michaelis M, Bliss J, Arnold SC, Hinsch N, Rothweiler F, Deubzer HE, Witt O, Langer K, Doerr HW, Wels WS, Cinatl J Jr.

Clin Cancer Res. 2008 Oct 15;14(20):6531-7. doi: 10.1158/1078-0432.CCR-08-0821.

Supplemental Content

Support Center